Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

被引：0
|
作者：
Chandra R Tate
Lyndsay V Rhodes
H Chris Segar
Jennifer L Driver
F Nell Pounder
Matthew E Burow
Bridgette M Collins-Burow
机构：
[1] Tulane University Health Sciences Center,Department of Medicine, Section of Hematology and Medical Oncology
来源：
Breast Cancer Research | / 14卷
关键词：
Panobinostat; LBH589; triple-negative breast cancer; xenograft; histone deacetylase inhibitor; E-cadherin; CDH1; epithelial-to-mesenchymal transition;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
    Tate, Chandra R.
    Rhodes, Lyndsay V.
    Segar, H. Chris
    Driver, Jennifer L.
    Pounder, F. Nell
    Burow, Matthew E.
    Collins-Burow, Bridgette M.
    BREAST CANCER RESEARCH, 2012, 14 (03)
  • [2] Histone deacetylase inhibitor panobinostat in combination with rapamycin confers enhanced efficacy against triple-negative breast cancer
    Wu, Kunlin
    Zhang, Huihao
    Zhou, Linlin
    Chen, Ling
    Mo, Caiqin
    Xu, Sunwang
    Lin, Junyu
    Kong, Lingjun
    Chen, Xiangjin
    EXPERIMENTAL CELL RESEARCH, 2022, 421 (01)
  • [3] Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells
    Schech, Amanda
    Kazi, Armina
    Yu, Stephen
    Shah, Preeti
    Sabnis, Gauri
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (08) : 1848 - 1857
  • [4] Development of a Novel Ferrocenyl Histone Deacetylase Inhibitor for Triple-Negative Breast Cancer Therapy
    Tang, Chu
    Du, Yang
    Liang, Qian
    Cheng, Zhen
    Tian, Jie
    ORGANOMETALLICS, 2018, 37 (14) : 2368 - 2375
  • [5] Targeting triple negative breast cancer with histone deacetylase inhibitors
    Fedele, Palma
    Orlando, Laura
    Cinieri, Saverio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (11) : 1199 - 1206
  • [6] Molecular profiling basal 2 subtypes of triple-negative breast cancer cells and their response to histone deacetylase inhibitor
    Lyn-Cook, Beverly
    Stovall, Destiny
    Word, Beverly
    Cotton, Ebony
    Hammons, George
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [7] Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4
    Gu, Zhangyuan
    Ye, Fugui
    Luo, Hong
    Li, Xiaoguang
    Gong, Yue
    Mao, Shiqi
    Jia, Xiaoqing
    Han, Xiangchen
    Han, Boyue
    Fu, Yun
    Cheng, Xiaolin
    Li, Jiejing
    Shao, Zhiming
    Wen, Peizhen
    Hu, Xin
    Zhuang, Zhigang
    JOURNAL OF BIOMEDICAL SCIENCE, 2025, 32 (01)
  • [8] Histone deacetylase inhibitors sensitize cancer stem cells to PARP inhibitors in triple-negative breast cancer
    Liu, Yajing
    Martin-Trevino, Rachel
    Shang, Li
    Davis, April
    Wicha, Max
    Liu, Suling
    Burness, Monika
    CANCER RESEARCH, 2015, 75
  • [9] A histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth with apoptosis in triple-negative breast cancer cells
    Ono, Hisako
    Sowa, Yoshihiro
    Iizumi, Yosuke
    Horinaka, Mano
    Taguchi, Tetsuya
    Sakai, Toshiyuki
    CANCER RESEARCH, 2018, 78 (13)
  • [10] Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells
    Rao, Rekha
    Balusu, Ramesh
    Fiskus, Warren
    Mudunuru, Uma
    Venkannagari, Sreedhar
    Chauhan, Lata
    Smith, Jacqueline E.
    Hembruff, Stacey L.
    Ha, Kyungsoo
    Atadja, Peter
    Bhalla, Kapil N.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (04) : 973 - 983
12345